Date: 2015-12-07
Type of information: Construction of new premises
Compound:
Company: Aptuit (UK)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On December 7, 2015, Aptuit announced it has commenced a growth program for 2016 to meet significant increase in demand from our customers in discovery, Chemistry, Manufacturing and Controls (CMC) and non-clinical development. During 2016 Aptuit will hire an additional 90 scientists to its facilities in Oxford and Verona, distributed across all areas. In addition there will be 16m$ of investment in facility upgrades and equipment to enhance our integrated development capabilities in the first of our aggressive expansion plans in our facilities. Aptuit’s existing expertise in Drug Design & Discovery will be strengthened with additional capacity and targeted investments in Hit Identification solutions, Translational and Biomarkers capabilities and Late Lead Optimization strategies. CMC will be strengthened with additional technologies in Clinical Manufacturing, in particular to its tableting and encapsulating; increasing the footprint and capabilities of its Formulation Development facilities to further expand Aptuit’s capability to successfully develop poorly soluble products; and specific investments in Quality Control and Material Sciences.
Financial terms:
Latest news:
